Determinants of resistance to antifolates: biochemical phenotypes, their frequency of occurrence and circumvention

F M Sirotnak1

  • 1Memorial Sloan-Kettering Cancer Center, Laboratory for Molecular Therapeutics, New York, NY 10021.

NCI Monographs : a Publication of the National Cancer Institute
|January 1, 1987
PubMed

Insights

Tumor cells develop resistance to antifolates through diverse biochemical changes affecting drug transport and targets like dihydrofolate reductase (DHFR). New drug design strategies analyze these resistance mechanisms for effective circumvention.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cancer Biology

Background:

  • Acquired resistance in tumor cells to antifolates is a significant clinical challenge.
  • Common resistance mechanisms involve alterations in membrane transport and the primary target, dihydrofolate reductase (DHFR).

Purpose of the Study:

  • To explore diverse biochemical alterations contributing to antifolate resistance.
  • To describe novel drug design approaches for circumventing acquired antifolate resistance.

Main Methods:

  • Analysis of quantitative and qualitative changes in membrane transport and DHFR.
  • Investigation of thymidylate synthase activity and 4-aminofolate polyglutamylation.
  • Kinetic analysis of biochemical phenotypes and structure-activity relationships.

Main Results:

  • Identified diverse biochemical alterations, including changes in DHFR, thymidylate synthase, and folate metabolism.
  • Developed drug design strategies incorporating kinetic and structure-activity analyses.

Conclusions:

  • Understanding the spectrum of biochemical resistance phenotypes is crucial for effective antifolate therapy.
  • New drug design approaches considering population genetics and resistance phenotypes can overcome acquired antifolate resistance.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...